Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
I-Mab $177 million follow-on secondary offering of ADSs
We advised the underwriters on the equity offering
Evernorth acquisition of MDLIVE
We are advising MDLIVE on the transaction
JOINN Laboratories HK$6.5 billion IPO
We advised JOINN Laboratories on its IPO and HKEX listing.
Reckitt Benckiser Group acquisition of Biofreeze
We are advising RB on the acquisition
Ayala Pharmaceuticals $25 million private placement
We advised the placement agent on the private placement of stock and warrants
InnoCare Pharma HK$3.04 billion share placement
We advised InnoCare Pharma in the placement of new shares
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Corvus Pharmaceuticals $34 million stock offering
We advised the underwriters on the equity offering
Biogen exchange offer
We advised the dealer managers on a debt exchange offer